TY - JOUR
T1 - LncRNAs and the cancer epigenome
T2 - Mechanisms and therapeutic potential
AU - Nadhan, Revathy
AU - Isidoro, Ciro
AU - Song, Yong Sang
AU - Dhanasekaran, Danny N.
N1 - Publisher Copyright:
© 2024
PY - 2024/11/28
Y1 - 2024/11/28
N2 - Long non-coding RNAs (lncRNAs) have emerged as critical regulators of epigenome, modulating gene expression through DNA methylation, histone modification, and/or chromosome remodeling. Dysregulated lncRNAs act as oncogenes or tumor suppressors, driving tumor progression by shaping the cancer epigenome. By interacting with the writers, readers, and erasers of the epigenetic script, lncRNAs induce epigenetic modifications that bring about changes in cancer cell proliferation, apoptosis, epithelial-mesenchymal transition, migration, invasion, metastasis, cancer stemness and chemoresistance. This review analyzes and discusses the multifaceted role of lncRNAs in cancer pathobiology, from cancer genesis and progression through metastasis and therapy resistance. It also explores the therapeutic potential of targeting lncRNAs through innovative diagnostic, prognostic, and therapeutic strategies. Understanding the dynamic interplay between lncRNAs and epigenome is crucial for developing personalized therapeutic strategies, offering new avenues for precision cancer medicine.
AB - Long non-coding RNAs (lncRNAs) have emerged as critical regulators of epigenome, modulating gene expression through DNA methylation, histone modification, and/or chromosome remodeling. Dysregulated lncRNAs act as oncogenes or tumor suppressors, driving tumor progression by shaping the cancer epigenome. By interacting with the writers, readers, and erasers of the epigenetic script, lncRNAs induce epigenetic modifications that bring about changes in cancer cell proliferation, apoptosis, epithelial-mesenchymal transition, migration, invasion, metastasis, cancer stemness and chemoresistance. This review analyzes and discusses the multifaceted role of lncRNAs in cancer pathobiology, from cancer genesis and progression through metastasis and therapy resistance. It also explores the therapeutic potential of targeting lncRNAs through innovative diagnostic, prognostic, and therapeutic strategies. Understanding the dynamic interplay between lncRNAs and epigenome is crucial for developing personalized therapeutic strategies, offering new avenues for precision cancer medicine.
KW - Cancer epigenetics
KW - Chromatin remodeling
KW - DNA methylation
KW - Epigenetic therapy
KW - Histone modification
KW - Long non-coding RNAs (lncRNAs)
KW - Oncogenes
KW - Precision oncology
KW - RNA interference (RNAi)
KW - Tumor suppressors
UR - http://www.scopus.com/inward/record.url?scp=85207365175&partnerID=8YFLogxK
U2 - 10.1016/j.canlet.2024.217297
DO - 10.1016/j.canlet.2024.217297
M3 - Review article
SN - 0304-3835
VL - 605
JO - Cancer Letters
JF - Cancer Letters
M1 - 217297
ER -